Citigroup rates Microport as a "buy" and lowers the target price to HKD 21.
Citigroup's research report states that based on Microport's (00853) management's latest guidance and recent sales trends, the bank has adjusted its earnings per share forecast. It is expected that earnings per share will increase by 59.4% in 2024 and by 43% in 2025 to reflect the company's strict cost control trend. The target price has been lowered from HKD 25 to HKD 21 to reflect the lower valuation of the heart valve business, with a buy rating.
MicroPort Scientific Redeems $700 Million Convertible Bonds Ahead of 2026 Maturity
MicroPort Scientific (HKG:0853) has fully redeemed and canceled its $700 million zero-coupon convertible bonds ahead of their maturity in 2026, according to a Wednesday filing with the Hong Kong Excha
HK stocks rose | Microport (00853) rose more than 5%, and the company completed the redemption of $700 million convertible bonds.
Microport (00853) rose more than 5%, as of press time, up 4.97%, at HKD 6.13, with a turnover of HKD 29.4151 million.
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Shanghai MicroPort Endovascular MedTech's (SHSE:688016) recent performance, when its stock has declined 12% over the past month. However, stock prices are
Microport (00853) has redeemed and cancelled all of its 2026 convertible bonds with a total principal amount of USD 700 million.
Microport (00853) announced that as of the date of this announcement, all of its exchangeable bonds due in 2026 (with a total principal amount of 700 million...) were
Microport (00853.HK) received a shareholding of 2.043 million shares from JPMorgan.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on June 5, 2024, Microport (00853.HK) received JPMorgan Chase & Co.'s shareholding of 2.043 million shares at an average price of HKD 6.3844 per share, with a total investment of approximately HKD 13.0433 million. After the shareholding, JPMorgan Chase & Co.'s latest holding position increased from 12.96% to 13.08% with a total of 239,995,487 shares.
MicroPort NeuroTech Limited's (HKG:2172) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With its stock down 11% over the past month, it is easy to disregard MicroPort NeuroTech (HKG:2172). However, stock prices are usually driven by a company's financials over the long term, which in t
Microport (00853.HK) received JPMorgan's shareholding of 2.4791 million shares.
According to the latest equity disclosure data from the Hong Kong Stock Exchange on May 30, 2024, Microport (00853.HK) received JPMorgan Chase & Co.'s shareholding of 2,479,100 shares at an average price of HKD 5.9242 per share, involving approximately HKD 14,686,700. After the shareholding, JPMorgan Chase & Co.'s latest position in the company increased from 12.89% to 13.02%, with a total holding of 239,044,679 shares.
MicroPort CardioFlow Prepares for Key 2024 AGM
MicroPort MedBot Announces Shareholders' Meeting
Shanghai MicroPort MedBot Gears Up for Crucial AGM
MicroPort Completes Major Convertible Loan Drawdown
Minimally Invasive Healthcare (00853.HK): Withdrawal of US$150 million convertible loan completed
On May 28, GLONGHUI | Minimally Invasive Healthcare (00853.HK) issued an announcement. All prerequisites under the convertible financing agreement have been met or exempted from the lender, and the total principal amount equal to the total initial commitment amount (US$150 million) of convertible shares has been withdrawn on May 28, 2024. The Board is pleased to further announce that as of the date of this announcement, the company has entered into a loan agreement with an independent financial institution to obtain credit support equivalent to $300 million to repay the 2026 convertible bonds.
MicroPort Scientific Corporation (HKG:853) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Those holding MicroPort Scientific Corporation (HKG:853) shares would be relieved that the share price has rebounded 26% in the last thirty days, but it needs to keep going to repair the recent damage
MicroPort Announces Board and Committee Lineup
Minimally Invasive Healthcare (00853): Luo Qiyi and Bloomberg retired as non-executive directors
Minimally Invasive Healthcare (00853) announced that Dr. Luo Qiyi and Mr. Bloomberg (both are non-executive directors of the company). They are investing more...
Insufficient Growth At Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) Hampers Share Price
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) price-to-earnings (or "P/E") ratio of 26.2x might make it look like a buy right now compared to the market in China, where around half
MicroPort Scientific Corporation's (HKG:853) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 3.4% Last Week
Key Insights Significant control over MicroPort Scientific by private companies implies that the general public has more power to influence management and governance-related decisions The top 4 shar
Changes in Hong Kong stocks | Minimally Invasive Healthcare (00853) is now down more than 6%, 23-year performance growth is slightly lower than expected, Nomura says the long-term debt problem is still difficult
Minimally Invasive Medicine (00853) is now down more than 6%. As of press release, it is down 6.22% to HK$6.8 million, with a turnover of HK$177 million.
Analysts Conflicted on These Healthcare Names: Cardiol Therapeutics (CRDL) and MicroPort Scientific (OtherMCRPF)
No Data